CCIA
PRTK

Campbell & Co Investment Adviser’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Campbell & Co Investment Adviser’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-17,000
Closed -$76K – 958
2021
Q4 		$76K Buy
+17,000
New +$80.6K 0.03% 584

Other funds holding PRTK

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
FIG
Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

Campbell & Co Investment Adviser's PRTK Position: Q1 2022 in Review

Campbell & Co Investment Adviser sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2022, closing a stake of 17,000 shares — an estimated $76K sold.

Campbell & Co Investment Adviser first reported a position in PRTK in Q4 2021 and held it in 1 quarter. The position peaked at $76K in Q4 2021. 100 funds tracked by Wall St. Rank hold PRTK as of Q1 2022.

  • Campbell & Co Investment Adviser reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 17,000 Paratek Pharmaceuticals, Inc. shares in Q1 2022, an estimated $76K.
  • Campbell & Co Investment Adviser first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2021 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Paratek Pharmaceuticals, Inc. position peaked at $76K in Q4 2021.
  • 100 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2022.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2022, filed 9 May 2022.